FDA approves efficacy supplement for Teva's Igalmi
The FDA cleared a third supplemental application for the dexmedetomidine film Igalmi, with a new label dated November 16, 2026.
The U.S. Food and Drug Administration approved an efficacy supplement for Igalmi, under NDA 215390, with a status date of November 13, 2026. The application lists Teva as the sponsor, and the submission was classified as an efficacy supplement, numbered as submission 3, with a status of approved.1
Igalmi is formulated as a sublingual or buccal film. The approved products include two strengths of dexmedetomidine hydrochloride, equivalent to 0.18 mg base and 0.12 mg base, both administered by the buccal or sublingual route.1
The review was processed under standard priority rather than priority review. The FDA record lists the review priority as standard.1
An updated product label tied to this approval is dated November 16, 2026, three days after the submission status date. The application documents include a label file dated 20261116, filed under the supplement 3 approval.1
No additional detail on the specific content of the label changes or the clinical basis for this efficacy supplement is included in the available FDA record. Readers following this product should watch for the posted label itself, which the agency has linked at the application's official page, for specifics on what changed.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.